Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
Published 14 Jan 2026
If the disease is in the lungs, why deliver the drugs everywhere else?
Published 14 Jan 2026
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
Published 14 Jan 2026
Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital?
Published 13 Jan 2026
It's sink or swim.
Published 13 Jan 2026
1 in 5 patients hospitalized with COPD are readmitted within 30 days of discharge - costing the US over $15 billion. But why?
Published 13 Jan 2026
Epigenetic silencing is emerging as one of biotech’s boldest bets, and nChroma Bio is racing to prove it in the clinic. ‘Functional cures have been elusive, but epigenetic silencers are uniquely suited to the biological challenge for hepatitis B patients,’ Jeff Walsh says.
Published 13 Jan 2026
Agentic AI makes a big splash in biopharma.
Published 12 Jan 2026
A clear message to investors: get in!
Published 12 Jan 2026
The status quo is over.
Published 12 Jan 2026
The FDA's second rejection of Atara's allogeneic T-cell therapy found the ALLELE trial no longer adequate for accelerated approval, a position Atara called a reversal
Published 9 Jan 2026
Biology’s data problem isn’t scarcity, it’s structure. Genomenon is addressing it by converting millions of scientific papers into usable genomic intelligence. “If Google had gone to school to get a PhD in molecular biology, that's what Mastermind is,” says CEO Mike Klein.
Published 9 Jan 2026
BillionToOne’s CEO, Dr. Oguzhan Atay, argues that “we are approaching biological problems from physics-based principles,” a mindset driving the company’s rapid growth, long-term focus, and pursuit of ultra-sensitive cancer and prenatal testing.
Published 8 Jan 2026
As regulators, pharma, and researchers search for more predictive tools, Emulate, Inc’s CEO, Jim Corbett, argues that Organ-on-a-Chip technology is still early. “If this were a nine-inning baseball game, we’re in the first inning - but the direction is very clear.”
Published 7 Jan 2026
The winter batch of FDA approvals featured therapies that compress intervention into fewer doses, fewer visits, and fewer points of failure.
Published 2 Jan 2026
“We’re really on the precipice of moving the company into that next stage of maturity,” Dr. Mike Exton
Published 8 Dec 2025
London · 15–19 November 2026
Explore Onyx’s independent guide to the events and make the most of your week in London.
